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Introduction
============

Dietary intake of fish-derived omega-3 polyunsaturated fatty acids (PUFAs) such as eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) has been recommended to reduce the risk of cardiovascular disease^[@bib1]--[@bib4])^. Omega-3 PUFAs have been demonstrated to possess anti-inflammatory, anti-fibrotic, and cardioprotective properties and improve vascular function^[@bib5]--[@bib9])^. Atherosclerosis and inflammation are reported to be implicated in the pathogenesis of aortic aneurysms^[@bib10],\ [@bib11])^. However, it is still unclear omega-3 PUFAs are implicated in the pathogenesis of aortic aneurysms as well as coronary artery disease (CAD). We previously reported that dietary intake of EPA and DHA prevented development of abdominal aortic aneurysms (AAAs) through the inhibition of macrophagemediated inflammation in a mouse model^[@bib12])^. Therefore, we assessed serum levels of omega-3 PUFAs in patients with AAA and investigated the association with size of AAA.

Methods
=======

Study Subjects
--------------

We enrolled 86 consecutive patients who were admitted to Juntendo University Hospital for the purpose of treatment for AAA by elective Endovascular Aneurysm Repair (EVAR) and conventional surgical repair from January 2013 to June 2016. We measured serum concentrations of PUFAs \[EPA, DHA, and arachidonic acid (AA)\] on admission. Eleven patients were excluded because 1 patient had an infected aneurysm, 1 patient had an endoleak after previous EVAR, 7 patients had taken pure EPA and 2 patients had received hemodialysis. Eight patients had not undergone three-dimensional (3D) reconstructed computed tomographic (CT) scan imaging before surgery. Finally, we analyzed 67 patients. We investigated whether serum omega-3 PUFAs (EPA and DHA), AA and the EPA/AA ratio are associated with the size of AAA. All subjects provided informed consent, the study protocol conforms to the ethical guidelines of the 1975 Declaration of Helsinki, and the study was approved by the ethical committee of Juntendo University Hospital.

Blood pressure (BP) was measured using a standard mercury sphygmomanometer. Height and weight were measured using an automated scale, and body mass index (BMI) was calculated as the weight in kilograms divided by the square of the height in meters. Hypertension was defined as systolic blood pressure ≥ 140 mmHg, diastolic blood pressure ≥ 90 mmHg, or currently taking antihypertensive medications. Dyslipidemia was defined as a low-density lipoprotein cholesterol (LDL-C) level ≥ 140 mg/dL, a high-density lipoprotein cholesterol (HDL-C) level \< 40 mg/dL, a triglycerides (TG) level ≥ 150 mg/dL, or currently taking lipid-lowering medications. Diabetes mellitus (DM) was defined as a documented history of diabetes treated with medications or hemoglobin A1c (HbA1c) of National Glycohemoglobin Standardization Program (NGSP) level ≥ 6.5%, fasting plasma glucose level ≥ 126 mg/dL, or non-fasting plasma glucose level ≥ 200 mg/dL.

Blood Sampling
--------------

Whole blood samples were drawn after overnight fasting within 24 h of admission. Serum levels of total cholesterol (TC), TG, and HDL-C were measured using standard enzymatic methods, and LDL-C values were calculated using the Friedewald formula^[@bib13])^. Plasma glucose concentrations and HbA1c, C-reactive protein (CRP), and creatinine (Cr) levels were measured using standardized methods. The estimated glomerular filtration rate was calculated based on the Japanese equation that uses serum Cr level, age, and gender as follows: estimated glomerular filtration rate (mL/min/1.73 m^2^) = 194 × Cr^−1.094^ × age^−0.287^ (female × 0.739)^[@bib14])^. Serum concentrations of EPA, DHA, and AA levels were measured by SRL Inc. (Tokyo, Japan) using standard laboratory protocols.

Computed Tomography, Measuring Aneurysm Diameter
------------------------------------------------

All 67 patients had undergone 3D reconstructed CT scan imaging before surgery. All CT angiographies were performed on a multidetector row CT scanner with 64 detectors (Aquilion; Toshiba, Tokyo, Japan). These CT images were reviewed on a 3D workstation (Synapse Vincent; Fujifilm, Tokyo, Japan). The aneurysm\'s maximum diameter was evaluated, with measurements obtained perpendicular to the centerline of aorta and aneurysm^[@bib15],\ [@bib16])^. The centerline of aorta and aneurysm was identified, and a curved multiplanar reconstruction (CPR) image was created. Then, the maximum diameter on CPR was determined using the cross section perpendicular to the centerline in this CPR image^[@bib17])^. Representative images used to determine the maximum diameter of AAA are shown in **[Fig. 1](#F1){ref-type="fig"}**.

![Representative images to determine the maximum AAA diameter\
The centerline of the aorta and aneurysm is identified and curved multiplanar reconstruction (CPR) images are created (A, B and C). Then, the maximum diameter is determined using the cross section perpendicular to the centerline in the CPR image (D).](jat-24-912-g001){#F1}

Coronary Artery Disease
-----------------------

CAD was defined as patients with a documented history of acute myocardial infarction, coronary artery bypass graft surgery, or documented presence of significant coronary artery stenosis (luminal narrowing ≥ 50%) in at least one major coronary artery by coronary angiography or multidetector computed tomographic angiography^[@bib18],\ [@bib19])^. Coronary angiography was performed according to standard methods^[@bib20])^. Coronary segments were analyzed according to the model of the American College of Cardiology/American Heart Association^[@bib21])^.

Statistical Analysis
--------------------

Continuous variables were expressed as mean ± standard deviation (SD), and categorical variables were reported as percentages. Statistical differences between the groups were analyzed by unpaired Student\'s *t*-test, the chi-square test, Fisher\'s exact test, or the Mann--Whitney--Wilcoxon rank-sum test, as appropriate. Correlations between 2 variables were determined by simple linear regression analysis. Spearman correlations were used when variables were not normally distributed. Multiple linear regression analysis was used to determine the factors independently contributing to the maximum AAA diameter among the variables with a *P* value \< 0.1 in univariate analysis (BMI, EPA and using *β* blocker). All statistical analyses were performed using JMP 12 software for Windows (SAS Institute, Cary, NC, USA.). Statistical significance was defined as a *P*-value \< 0.05.

Results
=======

Clinical Characteristics of Patients
------------------------------------

The baseline characteristics of all patients are shown in **[Table 1](#T1){ref-type="table"}**. Over all 67 patients, the mean age was 70 ± 9 years, BMI was 24.8 ± 2.9 kg/m^2^, and 60 (89.6%) were male. Nineteen (28.4%) patients had a history of current smoking. The number of hypertension, dyslipidemia, diabetes mellitus, and coronary artery disease patients were 52 (77.6%), 59 (88.1%), 13 (19.4%), and 40 (59.7%), respectively.

###### Characteristics of the patients

                                         All patients   CAD group      Non-CAD group   *P* value
  -------------------------------------- -------------- -------------- --------------- -----------
  Age, (years)                           70 ± 9         71 ± 9         70 ± 9          0.53
  Male, *n* (%)                          60 (89.6)      38 (95.0)      22 (81.5)       0.1
  Body mass index (kg/m^2^)              24.8 ± 2.9     24.4 ± 2.9     25.2 ± 2.9      0.26
  Systolic blood pressure (mmHg)         120 ± 13       119 ± 14       123 ± 11        0.19
  Diastolic blood pressure (mmHg)        69 ± 11        66 ± 11        73 ± 11         0.008
  Current smoking, *n* (%)               19 (28.4)      13 (32.5)      6 (22.2)        0.41
  Hypertension, *n* (%)                  52 (77.6)      30 (75)        22 (81.5        0.76
  Dyslipidemia, *n* (%)                  59 (88.1)      37 (92.5)      22 (81.5)       0.25
  Diabetes mellitus, *n* (%)             13 (19.4)      10 (25.0)      3 (11.1)        0.21
  Coronary artery disease, *n* (%)       40 (59.7)                                     
  Total cholesterol (mg/dL)              176 ± 31       169 ± 26       187 ± 34        0.015
  HDL-cholesterol (mg/dL)                45 ± 13        45 ± 14        46 ± 11         0.93
  LDL-cholesterol (mg/dL)                102 ± 28       96 ± 24        111 ± 32        0.028
  Triglyceride (mg/dL)                   143 ± 64       140 ± 61       149 ± 70        0.56
  HbA1c (NGSP) (%)                       6.0 ± 0.6      6.1 ± 0.7      5.9 ± 0.5       0.17
  Creatinine (mg/dL)                     0.86 ± 0.22    0.88 ± 0.24    0.82 ± 0.19     0.62
  eGFR (mL/min/1.73 m^2^)                70.1 ± 17.6    68.7 ± 16.8    72.3 ± 18.8     0.41
  CRP (mg/dL)                            0.28 ± 0.45    0.31 ± 0.53    0.24 ± 0.32     0.34
  EPA (µg/mL)                            75.2 ± 35.7    71.7 ± 29.7    80.5 ± 43.2     0.6
  DHA (µg/mL)                            146.1 ± 48.5   142.7 ± 45.3   151.0 ± 53.4    0.53
  AA (µg/mL)                             184.3 ± 53.7   182.8 ± 54.9   186.5 ± 52.8    0.74
  EPA/AA ratio                           0.44 ± 0.22    0.43 ± 0.22    0.45 ± 0.23     0.72
  Maximum AAA diameter (mm)              56.4 ± 8.9     56.9 ± 8.7     55.6 ± 9.2      0.69
  Medications                                                                          
      Antiplatelet, *n* (%)              23 (34.3)      20 (50.0)      3 (11.1)        0.001
      Calcium channel blocker, *n* (%)   31 (46.3)      14 (35.0)      17 (63.0)       0.028
      *β*-blocker, *n* (%)               24 (35.8)      19 (47.5)      5 (18.5)        0.019
      ACE inhibitor or ARB, *n* (%)      36 (53.7)      23 (57.5)      13 (48.2)       0.46
      Statin, *n* (%)                    46 (68.7)      33 (82.5)      13 (48.2)       0.006

Values are presented as means ± standard deviations. HDL = high-density lipoprotein, LDL = low-density lipoprotein, HbA1c = hemoglobin A1c, NGSP = national glycohemoglobin standardization program, eGFR = estimated glomerular filtration rate, CRP = C-reactive protein, EPA = eicosapentaenoic acid, DHA = docosahexaenoic acid, AA = arachidonic acid, AAA = abdominal aortic aneurysm, ACE = angiotensin converting enzyme, ARB = angiotensin II receptor blocker.

Serum PUFA Levels in Patients with AAA
--------------------------------------

As shown in **[Table 1](#T1){ref-type="table"}**, serum levels of EPA, DHA, and AA were 75.2 ± 35.7, 146.1 ± 48.5, and 184.3 ± 53.7 µg/mL, respectively. The EPA/AA ratio was 0.44 ± 0.22, and the median value was 0.41. We have previously reported serum levels of PUFAs in a healthy Japanese population living in an urban area. In subjects aged over 65 years, serum levels of EPA, DHA, and AA were 81.9 ± 31.1, 123.2 ± 27.0, and 119.8 ± 22.7 µg/mL, respectively. The EPA/AA ratio was 0.68 ± 0.22^[@bib22])^. Therefore, serum levels of EPA had a tendency to decrease with age, those of DHA, and AA had a tendency to increase with age, and the EPA/AA ratio was also relatively lower than in healthy Japanese subjects.

Correlations between Serum PUFA Levels and AAA Diameter
-------------------------------------------------------

Mean of the maximum AAA diameter was 56.4 ± 8.9 mm. There were no significant correlations between maximum AAA diameter and conventional risk factors (e.g., hypertension, dyslipidemia, diabetes mellitus, current smoking, and coronary artery disease). There were no significant correlations between serum levels of TC, HDL-C, LDL-C, TG, HbA1c, creatinine and CRP, and maximum AAA diameter. Although statins, *β* blockers, and angiotensin pathway inhibition (angiotensin converting enzyme inhibitors or angiotensin II receptor blockers) were pharmacological treatment strategy for AAA, only *β* blocker usage was associated with AAA diameter (**[Table 2](#T2){ref-type="table"}**).

###### Univariate linear regression analysis for correlates of maximum AAA diameter

                             *r*      *P* value
  -------------------------- -------- -----------
  Age                        −0.043   0.73
  Gender                     0.009    0.94
  Body mass index            0.24     0.05
  Systolic blood pressure    −0.091   0.46
  Diastolic blood pressure   −0.15    0.22
  Current smoking            0.088    0.47
  Hypertension               0.075    0.54
  Dyslipidemia               −0.11    0.36
  Diabetes mellitus          −0.037   0.77
  Coronary artery disease    0.05     0.69
  Total cholesterol          0.077    0.53
  HDL-cholesterol            −0.13    0.28
  LDL-cholesterol            0.16     0.18
  Triglyceride               0.088    0.48
  HbA1c                      0.007    0.95
  Creatinine                 −0.054   0.66
  eGFR                       0.091    0.46
  CRP                        −0.039   0.75
  EPA                        −0.32    0.007
  DHA                        −0.14    0.25
  AA                         0.026    0.83
  EPA/AA ratio               −0.32    0.008
  Antiplatelet               0.021    0.87
  Calcium channel blocker    0.15     0.23
  *β*-blocker                0.21     0.091
  ACE inhibitor or ARB       0.015    0.91
  Statin                     −0.032   0.79

Values are presented as means ± standard deviations. CAD = coronary artery disease, HDL = high-density lipoprotein, LDL = low-density lipoprotein, HbA1c = hemoglobin A1c, NGSP = national glycohemoglobin standardization program, eGFR = estimated glomerular filtration rate, CRP = C-reactive protein, EPA = eicosapentaenoic acid, DHA = docosahexaenoic acid, AA = arachidonic acid, ACE = angiotensin converting enzyme, ARB = angiotensin II receptor blocker.

As shown in **[Fig. 2](#F2){ref-type="fig"}**, serum levels of EPA and the EPA/AA ratio were negatively correlated with maximum AAA diameter (*r* = −0.32, *P* = 0.0073, and *r* = −0.32, *P* = 0.0075, respectively). However, there were no significant correlations between maximum AAA diameter and serum levels of DHA and AA. Multiple liner regression analysis showed that serum levels of EPA were significant independent factor contributing to maximum AAA diameter (EPA: *β* = −0.269, *P* = 0.02, BMI: *β* = 0.125, *P* = 0.2, using *β* blocker: *β* = −0.109, *P* = 0.3) (**[Table 3](#T3){ref-type="table"}**).

![Correlations between serum levels of PUFAs and maximum AAA diameter\
Serum levels of EPA (A), and the EPA/AA ratio (B) were significantly negatively associated with the maximum AAA diameter but not serum levels of DHA (C) or AA (D).\
AA: arachidonic acid, AAA: abdominal aortic aneurysm, DHA: docosahexaenoic acid, EPA: eicosapentaenoic acid, PUFAs: polyunsaturated fatty acids.](jat-24-912-g002){#F2}

###### Multiple liner regression analysis for correlates of maximum AAA diameter

                *β*      SE      *P* value
  ------------- -------- ------- -----------
  EPA           −0.269   0.03    0.28
  BMI           0.125    0.364   0.29
  *β* blocker   −0.109   1.1     0.36

R^2^ = 0.11, *P* = 0.05

Multiple linear regression analysis was performed among variables with a *P* value \< 0.1 in univariate analysis (BMI, EPA and using *β* blocker). Using *β* blocker was assigned a value of 1. Non using *β* blocker was assigned a value of 0.

Comparison between Serum PUFA Levels between the CAD and the Non-CAD Groups
---------------------------------------------------------------------------

The patients were also divided into a CAD group and a non-CAD group. Characteristics of the patients in both groups are shown in **[Table 1](#T1){ref-type="table"}**. The EPA/AA ratio was not significantly different between the two groups (0.43 ± 0.22 vs. 0.45 ± 0.23, *P* = 0.72). Serum levels of EPA in the non-CAD group tended to correlate with maximum AAA diameter (*r* = −0.38, *P* = 0.050), and the EPA/AA ratio in the non-CAD group was negatively correlated with maximum AAA diameter (*r* = −0.42, *P* = 0.030). Whereas maximum AAA diameter tended to be associated with both serum levels of EPA and the EPA/AA ratio (*r* = −0.26, *P* = 0.10, and *r* = −0.28, *P* = 0.079, respectively) in the CAD group (**[Fig. 3](#F3){ref-type="fig"}**).

![Correlations between serum levels of EPA and EPA/AA ratio and maximum AAA diameter in the CAD and the non-CAD group\
Both serum levels of EPA in the non-CAD group (white circles) and the CAD group (black circles) tended to negatively correlate with maximum AAA diameter (A). The EPA/AA ratio in the non-CAD group (white circles) was significantly negatively correlated with maximum AAA diameter, whereas maximum AAA diameter tended to be negatively associated those in the CAD group (black circles) (B).\
AA: arachidonic acid, AAA: abdominal aortic aneurysm, CAD: coronary artery disease, EPA: eicosapentaenoic acid.](jat-24-912-g003){#F3}

Correlations between Serum PUFA Levels and Growth Rate of AAA Diameter
----------------------------------------------------------------------

We investigated the rate of AAA expansion. Among all study subjects, for 41 patients previously performed CT scans over at least six-month intervals could be reviewed retrospectively. We evaluated aneurysms by measuring the traditional maximum minor-axis diameter using the cross sectional slice. Mean of the maximum minor-axis AAA diameter was 48.8 ± 6.1 mm. Mean follow-up time was 30.6 ± 22.5 months (range 6--77 months). The mean monthly growth rate of maximum minor-axis AAA diameter was 0.28 ± 0.12 mm/month (range 0.11--0.64 mm). Systolic blood pressure and diastolic blood pressure were positively correlated with monthly growth rate of maximum minor-axis AAA diameter (*r* = 0.39, *P* = 0.0097, and *r* = 0.31, *P* = 0.045, respectively) and serum levels of creatinine was negatively correlated with monthly growth rate of maximum minor-axis AAA diameter (*r* = −0.33, *P* = 0.035). Serum levels of EPA and the EPA/AA ratio were negatively correlated with AAA growth rate (*r* = −0.43, *P* = 0.0056, and *r* = −0.33, *P* = 0.033, respectively), as shown in **[Fig. 4](#F4){ref-type="fig"}**.

![Correlations between serum levels of EPA and EPA/AA ratio and growth rate of maximum minor-axis diameter of AAA\
Both serum levels of EPA (A), and the EPA/AA ratio (B) were significantly negatively associated with the growth rate of maximum minor-axis diameter of AAA.\
EPA: eicosapentaenoic acid, AAA: abdominal aortic aneurysm, AA: arachidonic acid.](jat-24-912-g004){#F4}

Discussion
==========

To our knowledge, this is the first study to assess the association between serum levels of PUFAs and the development of AAA in a clinical setting. In patients with AAA, serum levels of EPA had a tendency to decrease with age, DHA, and AA, had a tendency to increase with age, and the EPA/AA ratio was also relatively lower than in healthy Japanese subject^[@bib22])^. Moreover, there were significant negative correlations between serum levels of EPA and the EPA/AA ratio and maximum AAA diameter and growth rate of AAA diameter.

Compared with our previous report of serum PUFA levels in healthy Japanese subjects^[@bib22])^, patients with AAA showed low EPA levels and EPA/AA ratios. Several previous studies have demonstrated that serum levels of EPA and EPA/AA ratios in patients with CAD are lower than those in normal subjects. The JELIS study showed that the average ratio of EPA/AA serum levels was 0.6 in the primary and secondary prevention study^[@bib2],\ [@bib23])^. In the Tochigi Ryoma EPA/AA Trial in Coronary Artery Disease (TREAT-CAD), the EPA/AA ratio was measured in 428 patients who underwent diagnostic coronary angiography because they were suspected to have CAD. The average EPA/AA ratio was 0.49, and its median value was 0.37^[@bib24])^. We also evaluated serum PUFA levels in patients with acute coronary syndrome in a metropolitan area in Japan. The EPA/AA ratio was 0.46 in 72 patients^[@bib25])^. The EPA/AA ratio of serum levels in our study subjects was 0.44 ± 0.22, which is equivalent to previous reports in patients with CAD. In addition, serum levels of EPA and the EPA/AA ratio in patients with AAA in the non-CAD group were equivalent to those, in the CAD group, suggesting that serum levels of EPA, and the EPA/AA ratio in patients with AAA is relatively low regardless of the presence of CAD.

Serum levels of EPA and the EPA/AA ratio were significantly negatively correlated with maximum AAA diameter and the growth rate of AAA. AAA formation is associated with chronic aortic wall inflammation, which is linked to the production of elastinand collagen-degrading enzymes such as matrix metalloproteinases (MMP)-2 and MMP-9^[@bib26],\ [@bib27])^. We have reported that, in the AAA model that was developed by angiotensin II infusion in apolipoprotein E-deficient mice, administration of both EPA and DHA suppressed the infiltration of macrophages and that down-regulation of inflammatory cytokines and enzymes in the aortic wall resulted in inhibition of the development of AAA^[@bib12])^. Wang *et al.* have also demonstrated that an EPA-rich diet can attenuate AAA formation in a murine CaCl~2~-induced AAA model by suppressing tissue remodeling^[@bib28])^. These results from *in vivo* studies could account for the association between lower EPA and EPA/AA ratio and the severity of AAA.

Although DHA as well as EPA has been recommended to reduce the risk of cardiovascular disease, Yagi *et al.* reported that the serum levels of DHA, but not EPA, are associated with the endothelial function in patients with CAD^[@bib29])^. Furthermore, we have reported that both EPA and DHA inhibited the development of AAA in a mouse model^[@bib12])^. However, serum DHA levels did not correlate with AAA formation in our study population. The mechanism(s) by which only EPA levels were associated with AAA formation is unclear. Therefore, further studies will be required to clarify the different role between DHA and EPA in the pathogenesis of AAA.

Conventional risk factors for AAA are advanced age, male gender, smoking, hypertension, dyslipidemia, and CAD. Pharmacological treatment strategies for AAA are statins, *β* blockers, and angiotensin pathway inhibition. Several cohort studies have implicated that statins are associated with lower AAA growth rates^[@bib30],\ [@bib31])^. In this study, the CAD group tended to have more conventional risk factors than the non-CAD group, and the CAD group tended to use more pharmacological treatment for AAA than the non-CAD group, especially statins and *β* blockers. There were stronger correlations of serum levels of EPA and EPA/AA ratio with maximum AAA diameter in the non-CAD group than in the CAD group. These results suggest that low serum levels of EPA and a low EPA/AA ratio contribute more to the development of AAA in patients with fewer conventional risk factors.

This study has several limitations. Firstly, this study was a cross-sectional survey. Therefore, we could not show the causal relationship between PUFA levels and the development of AAA. Secondly, the study sample size was relatively small. Although this study showed a significant correlation between EPA and AAA, a larger prospective study is needed to confirm our results.

Conclusion
==========

The EPA level and EPA/AA ratio may be relatively lower in patients with AAA than in healthy Japanese subjects and equivalent to those in patients with CAD previously reported. Low levels of serum EPA and a low EPA/AA ratio are associated with the severity of AAA. Further investigation would be required to assess whether low serum levels of EPA and a low EPA/AA ratio are potential therapeutic targets.
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